Alpha Cognition to announce 2024 financial results March 31

Alpha Cognition Inc. plans to announce its financial results for the fourth quarter and full year of 2024 on March 31, 2025. This report will come after the markets close. Following the announcement, the company will hold a conference call to discuss the results. The call will be open to participants using specific dial-in numbers. To avoid long wait times, callers can use a feature to connect with the company 15 minutes before the event starts. A live audio webcast will also be available for those who prefer to listen online. Alpha Cognition is a biopharmaceutical company that focuses on developing treatments for neurodegenerative diseases, including Alzheimer's. Their drug, ZUNVEYL, is designed to treat Alzheimer's disease and is noted for causing fewer gastrointestinal side effects compared to current treatments. It targets specific receptors in the brain that help improve cognition. The company is also working on ALPHA-1062, which, in combination with another drug, aims to help those with moderate to severe Alzheimer's dementia. This treatment may also benefit patients with cognitive impairments resulting from mild traumatic brain injury. The announcement includes forward-looking statements that express the company's views on future events. However, these statements carry risks and uncertainties that could lead to actual results differing significantly from what is expected. The company advises caution when interpreting these forward-looking comments.